Function-Driven Immune Therapeutics
DATA DRIVEN. ASSET FOCUSED. BIOLOGY FIRST.
At Feromics, our scientists, engineers, and clinicians work from a single starting point: function. What immune cells do — not just what they contain — determines therapeutic outcome. Every solution Feromics develops, every candidate it advances, and every partnership it builds is grounded in that conviction. Our platform generates novel drug candidates, proprietary functional datasets, and collaborative research programs — all driven by verified biology and designed to deliver assets that translate.
Solutions
DATA DRIVEN, ASSET FOCUSED.
IMMUNOTHERAPY
-
Uncover molecular pathways driving immune cell cytotoxicity and function to advance CAR-T and CAR-Treg therapies.
-
Applications:
— Develop and optimize CAR-T constructs to enhance efficacy and persistence.
— Develop and optimize CAR-Treg constructs to modulate immune responses in autoimmune diseases.
PRECISION MEDICINE
-
Derisk preclinical and clinical development: optimize efficacy and patient outcomes through personalized immune profiling.
-
Donor Intelligence: identify and select high-performance donors for allogeneic immunotherapies based on verified functional killing data — ensuring the cells going into manufacturing are the cells most likely to produce durable clinical outcomes.
-
Personalized immunotherapy: match each patient to the treatment most likely to work based on their individual immune profile.
-
Companion diagnostics: develop predictive biomarkers to stratify patients for clinical trials — identifying responders before treatment begins.
R & D
REVOLUTIONARY
While most platforms attempt to decipher omics data from functionally heterogeneous immune cells — using AI to find signals in a noisy mixture — Feromics takes a different approach. Our biotechnology and workflow accurately identify, isolate, and analyze immune cell phenotypes specific to a disease, producing high-confidence, actionable data that powers AI models and informs the design of novel immunotherapies.
-
Oncology — Identifying tumor-killing immune cell phenotypes, serial killing behavior, and resistance signatures to advance CAR-T, TIL, and engager-based therapies.
-
Autoimmune Disease — Characterizing pathogenic B and T cell programs driving autoimmune pathology, enabling precise therapeutic targeting of disease-causing cells while preserving healthy immune function.
Platform
INNOVATIVE TECHNOLOGY & WORKFLOW
Feromics' Intelligent Design™ platform uses a bottom-up, engineering-driven workflow to identify, isolate, and analyze unique immune cell phenotypes associated with disease. Every measurement begins with function — what the cell does — before any molecular data is collected. These function-labeled single-cell datasets power our AI-driven bioinformatics, decoding the molecular programs that drive immune behavior in disease.
The result is an asset-focused drug discovery and development platform that moves from functional observation to validated targets, therapeutic candidates, and clinical predictions — entirely in-house.
Strategy
LEADING THE WAY IN PRECISION IMMUNOTHERAPY
Feromics' strategy is built on a simple but powerful premise: functional biology produces better data, better data produces better AI, and better AI produces better medicine. We pursue this through three parallel tracks — building the most defensible functional immunomics dataset in existence, translating platform discoveries into proprietary therapeutic assets, and partnering with the organizations best positioned to bring functional intelligence into clinical development at scale.
PIPELINE
Feromics is actively applying the Intelligent Design™ platform to develop proprietary therapeutic assets — discoveries that belong entirely to Feromics, generated through our own functional immunomics workflow.
Our pipeline spans two development tracks. Ex vivo programs focus on function-selected T and NK cell engineering — starting with the highest-intrinsic-fitness cells and designing for durability in demanding disease environments. In vivo programs explore next-generation delivery approaches to enhance immune fitness directly inside the patient.
Every candidate is powered by AI models trained on verified functional data — moving from functional observation to validated target to therapeutic candidate with a clarity and confidence that trial-and-error development cannot match.